Liquidia (NASDAQ:LQDA) Insider Sells $26,749.89 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 831 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $32.19, for a total value of $26,749.89. Following the sale, the insider owned 154,506 shares of the company’s stock, valued at approximately $4,973,548.14. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Scott Moomaw also recently made the following trade(s):

• On Monday, October 13th, Scott Moomaw sold 4,900 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total value of $114,709.00.

Liquidia Stock Up 0.5%

Liquidia stock opened at $33.92 on Friday. The firm has a fifty day moving average price of $26.04 and a two-hundred day moving average price of $21.73. Liquidia Corporation has a fifty-two week low of $10.37 and a fifty-two week high of $34.08. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -23.56 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. The company had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.Liquidia’s revenue for the quarter was up 1106.7% on a year-over-year basis. As a group, analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Large investors have recently modified their holdings of the stock. Caxton Associates LLP bought a new stake in shares of Liquidia during the third quarter valued at approximately $389,000. TCG Crossover Management LLC acquired a new position in Liquidia during the 3rd quarter worth $38,887,000. Voloridge Investment Management LLC bought a new position in Liquidia in the 3rd quarter valued at $12,571,000. Scientech Research LLC acquired a new stake in shares of Liquidia in the 3rd quarter valued at $237,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Liquidia during the third quarter worth $2,137,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LQDA has been the topic of a number of recent research reports. Wells Fargo & Company assumed coverage on shares of Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 price target on the stock. HC Wainwright increased their target price on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Needham & Company LLC upped their price target on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Raymond James Financial reissued a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a report on Tuesday, November 4th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $49.00 target price on shares of Liquidia in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).